Akari Therapeutics

Akari Therapeutics, Plc (NASDAQ: AKTX) is an oncology biotechnology company headquartered in Tampa, Florida, developing antibody-drug conjugates (ADCs) built on a novel PH1 RNA spliceosome-modulating payload that disrupts RNA splicing in cancer cells and triggers immune-mediated tumor killing.

Company Info

Sector:Oncology / ADC

Headquarters:Tampa, Florida, USA (with London, UK offices)

Founded:2013

Website:www.akaritx.com/

Clinical Development Pipeline

AKTX-101 (PH1 payload + Trop2 ADC)

Target: Trop2 / PH1 spliceosome-modulating payload

Solid tumors (lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate)

Preclinical

Phase 1

Phase 2

Phase 3

Approved

AKTX-102 (bispecific ADC)

Target: CEACAM5 / PH1 payload

Solid tumors

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Recent News

No recent news updates available for this company.

Leadership Team

Abizer Gaslightwala

President & CEO

Kameel D. Farag

Interim CFO

Dr. Satyajit Mitra, PhD

Executive Director and Head of Oncology

Careers & Job Openings

See all open roles

—

Apply Now →